Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma

Neuroblastoma is a lethal childhood solid tumor of developing peripheral nerves. Two percent of children with neuroblastoma develop opsoclonus myoclonus ataxia syndrome (OMAS), a paraneoplastic disease characterized by cerebellar and brainstem-directed autoimmunity but typically with outstanding can...

Full description

Saved in:
Bibliographic Details
Published inCell reports (Cambridge) Vol. 42; no. 8; p. 112879
Main Authors Rosenberg, Miriam I., Greenstein, Erez, Buchkovich, Martin, Peres, Ayelet, Santoni-Rugiu, Eric, Yang, Lei, Mikl, Martin, Vaksman, Zalman, Gibbs, David L., Reshef, Dan, Salovin, Amy, Irwin, Meredith S., Naranjo, Arlene, Ulitsky, Igor, de Alarcon, Pedro A., Matthay, Katherine K., Weigman, Victor, Yaari, Gur, Panzer, Jessica A., Friedman, Nir, Maris, John M.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 29.08.2023
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Neuroblastoma is a lethal childhood solid tumor of developing peripheral nerves. Two percent of children with neuroblastoma develop opsoclonus myoclonus ataxia syndrome (OMAS), a paraneoplastic disease characterized by cerebellar and brainstem-directed autoimmunity but typically with outstanding cancer-related outcomes. We compared tumor transcriptomes and tumor-infiltrating T and B cell repertoires from 38 OMAS subjects with neuroblastoma to 26 non-OMAS-associated neuroblastomas. We found greater B and T cell infiltration in OMAS-associated tumors compared to controls and showed that both were polyclonal expansions. Tertiary lymphoid structures (TLSs) were enriched in OMAS-associated tumors. We identified significant enrichment of the major histocompatibility complex (MHC) class II allele HLA-DOB∗01:01 in OMAS patients. OMAS severity scores were associated with the expression of several candidate autoimmune genes. We propose a model in which polyclonal auto-reactive B lymphocytes act as antigen-presenting cells and drive TLS formation, thereby supporting both sustained polyclonal T cell-mediated anti-tumor immunity and paraneoplastic OMAS neuropathology. [Display omitted] •OMAS-associated neuroblastomas contain more B and T cells than control neuroblastomas•OMAS-associated neuroblastoma B and T cell repertoires are diverse, with small clones•Tertiary lymphoid structures are enriched in OMAS-associated neuroblastomas•Gene expression correlated to neurological symptom severity nominates autoantigens Rosenberg et al. sought features of the systemic immune response underlying improved tumor outcomes and neurological dysfunction in patients with opsoclonus myoclonus ataxia syndrome (OMAS), an autoimmune disease caused by neuroblastoma. Diverse B and T cell lymphocytic infiltration organized in enriched tertiary lymphoid structures predominate in OMAS-associated tumors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
AUTHOR CONTRIBUTIONS
M.I.R. designed the project with J.A.P. and led the project; performed tumor imaging, data analysis, and synthesis; and wrote the manuscript with contributions from all authors. E.G. led TCR analysis with contributions from D.R. and supervision by N.F. M.B. carried out bioinformatics analysis, including differential expression, SNP analysis, immune landscape signature, and HLA analyses, and implementation of immune subtype pipeline. L.Y. contributed network analyses, statistical analysis, and bioinformatics. Z.V. carried out transcriptome analysis. M.M. carried out machine learning experiments (XGBoost) and contributed statistical and bioinformatic analysis. A.P. led BCR analysis under the supervision of G.Y. E.S.-R. carried out the histopathological scoring and immunohistochemical phenotyping. A.S. contributed to immunohistochemical analyses. D.L.G. carried out additional immune subtype analysis and bioinformatics. I.U. contributed to bioinformatic analysis. A.N., M.S.I., K.K.M., and P.A.d.A. led the clinical trial from which samples for this study were obtained. V.W. supervised transcriptome analysis and HLA analysis and design and provided bioinformatics support. J.M.M. supervised the project.
ISSN:2211-1247
2211-1247
DOI:10.1016/j.celrep.2023.112879